ATE405266T1 - MONOCYCLIC OR BIZYCLIC CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF FACTOR XA - Google Patents

MONOCYCLIC OR BIZYCLIC CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF FACTOR XA

Info

Publication number
ATE405266T1
ATE405266T1 AT01274110T AT01274110T ATE405266T1 AT E405266 T1 ATE405266 T1 AT E405266T1 AT 01274110 T AT01274110 T AT 01274110T AT 01274110 T AT01274110 T AT 01274110T AT E405266 T1 ATE405266 T1 AT E405266T1
Authority
AT
Austria
Prior art keywords
heterocycles
inhibitors
factor
monocyclic
carbocycles
Prior art date
Application number
AT01274110T
Other languages
German (de)
Inventor
Irina Jacobson
Ruth Wexler
Jennifer Qiao
Suanne Nakajima
Mimi Quan
Shuaige Wang
Joanne Smallheer
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Application granted granted Critical
Publication of ATE405266T1 publication Critical patent/ATE405266T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • C07D223/10—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)

Abstract

The present application describes monocyclic or bicyclic carbocycles and heterocycles and derivatives thereof of Formula I: or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.
AT01274110T 2000-11-06 2001-10-30 MONOCYCLIC OR BIZYCLIC CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF FACTOR XA ATE405266T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24610700P 2000-11-06 2000-11-06
US31355201P 2001-08-20 2001-08-20

Publications (1)

Publication Number Publication Date
ATE405266T1 true ATE405266T1 (en) 2008-09-15

Family

ID=26937728

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01274110T ATE405266T1 (en) 2000-11-06 2001-10-30 MONOCYCLIC OR BIZYCLIC CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF FACTOR XA

Country Status (9)

Country Link
US (2) US6710058B2 (en)
EP (1) EP1337251B1 (en)
JP (1) JP2004536084A (en)
AT (1) ATE405266T1 (en)
CA (1) CA2429113A1 (en)
DE (1) DE60135485D1 (en)
ES (1) ES2310540T3 (en)
HU (1) HUP0401832A2 (en)
WO (1) WO2002102380A1 (en)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI290136B (en) 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
WO2003000657A1 (en) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
MXPA04004830A (en) * 2001-11-22 2004-07-30 Ono Pharmaceutical Co Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient.
TW200307667A (en) * 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
US7405234B2 (en) * 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7205318B2 (en) * 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
WO2004101529A1 (en) * 2003-05-19 2004-11-25 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic compound and medical use thereof
GB0314299D0 (en) 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
GB0314373D0 (en) * 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
GB0314370D0 (en) * 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
JP2006527732A (en) * 2003-06-19 2006-12-07 グラクソ　グループ　リミテッド 3-sulfonylamino-pyrrolidin-2-one derivatives as inhibitors of factor XA
CA2531619A1 (en) * 2003-07-16 2005-01-27 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
US7169795B2 (en) * 2003-09-30 2007-01-30 Bristol Myers Squibb Company Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
US7199149B2 (en) 2003-10-01 2007-04-03 Bristol Myers Squibb Company Monocyclic and bicyclic lactams as factor Xa inhibitors
US7388027B2 (en) * 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7696241B2 (en) * 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US8710232B2 (en) * 2004-04-22 2014-04-29 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives used as TAFIa inhibitors
RU2361872C2 (en) * 2004-05-26 2009-07-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Cynnamide compound
MY145822A (en) * 2004-08-13 2012-04-30 Neurogen Corp Substituted biaryl piperazinyl-pyridine analogues
AU2005284727A1 (en) * 2004-09-17 2006-03-23 University Of Massachusetts Compositions and their uses for lysosomal enzyme deficiencies
DE602005019602D1 (en) 2004-10-26 2010-04-08 Eisai R&D Man Co Ltd AMORPHIC FORM OF A CINEMA ACID AMID CONNECTION
JPWO2006104280A1 (en) * 2005-03-31 2008-09-11 武田薬品工業株式会社 Diabetes prevention and treatment
CN101309916A (en) * 2005-11-18 2008-11-19 卫材R&D管理有限公司 Process for preparing cinnamamide derivatives
US20090048448A1 (en) * 2005-11-18 2009-02-19 Ikuo Kushida Salts of cynnamide compound or solvates thereof
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
JPWO2007135969A1 (en) * 2006-05-19 2009-10-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 Urea-cinnamide derivatives
KR20090016591A (en) * 2006-05-19 2009-02-16 에자이 알앤드디 매니지먼트 가부시키가이샤 Cinnamid derivatives of heterocycle type
CL2008000582A1 (en) * 2007-02-28 2008-06-27 Eisai R&D Man Co Ltd CYCLE COMPOUNDS DERIVED FROM CONDENSED OXIMORPHOLINE; PHARMACES THAT INCLUDE SUCH COMPOUNDS; AND ITS USE TO TREAT ALZHEIMER'S DISEASE, SENILE DEMENTIA, DOWN SYNDROME OR AMYLOIDOSIS.
US20080306272A1 (en) * 2007-05-16 2008-12-11 Eisai R&D Management Co., Ltd. One-pot methods for preparing cinnamide derivatives
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
BRPI0815773A2 (en) * 2007-08-31 2019-09-24 Eisai R&D Man Co Ltd compound and medicine.
WO2009096349A1 (en) * 2008-01-28 2009-08-06 Eisai R & D Management Co., Ltd. Crystalline cinnamide compounds or salts thereof
WO2009119528A1 (en) * 2008-03-24 2009-10-01 武田薬品工業株式会社 Heterocyclic compound
DE102008035552A1 (en) * 2008-07-30 2010-02-04 Bayer Schering Pharma Aktiengesellschaft Substituted pyridines and their use
MX2011010218A (en) 2009-04-02 2011-10-10 Merck Patent Gmbh Autotaxin inhibitors.
CN102369186B (en) 2009-04-02 2014-07-09 默克专利有限公司 Piperidine and piperazine derivatives as autotaxin inhibitors
EP2445879A1 (en) * 2009-06-25 2012-05-02 Institut Univ. de Ciència i Tecnologia, S.A. N-(2-oxo-1-phenylpiperidin-3-yl) sulfonamides for the identification of biological and pharmacological activity
ES2354550B1 (en) 2009-06-26 2011-11-15 Institut Univ. De Ciència I Tecnologia, S.A. LIBRARY OF N- (1-PHENYL-2-OXO-3-PIPERIDIL) SULFONAMIDS FOR THE DISCOVERY OF DRUGS.
KR20130113948A (en) 2010-05-17 2013-10-16 어레이 바이오파마 인크. Piperidinyl-substituted lactams as gpr119 modulators
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
WO2011160206A1 (en) 2010-06-23 2011-12-29 Morin Ryan D Biomarkers for non-hodgkin lymphomas and uses thereof
TWI447141B (en) * 2010-08-04 2014-08-01 Apaq Technology Co Ltd Conductive polymer and device thereof
BR112013005806B1 (en) 2010-09-10 2022-05-10 Epizyme, Inc METHODS TO DETECT WHETHER AN INDIVIDUAL IS A CANDIDATE FOR TREATMENT WITH OR RESPONSIVE TO AN EZH2 INHIBITOR AND THERAPEUTIC USES OF SUCH EZH2 INHIBITOR
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
EP2638016B1 (en) 2010-11-11 2014-10-01 Sanofi Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives
WO2012118812A2 (en) 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
TW201733984A (en) 2011-04-13 2017-10-01 雅酶股份有限公司 Substituted benzene compounds
JO3363B1 (en) 2011-04-13 2019-03-13 Epizyme Inc Heterocyclic benzene compounds with aryl or aryl
EP2731942B1 (en) 2011-07-13 2015-09-23 Novartis AG Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
US9227982B2 (en) 2011-07-13 2016-01-05 Novartis Ag 4-oxo-3,5,7,8-tetrahydro-4H-pyrano[4,3-d]pyrminidinyl compounds for use as tankyrase inhibitors
AU2012282076A1 (en) * 2011-07-13 2014-02-27 Novartis Ag 4 - piperidinyl compounds for use as tankyrase inhibitors
AR088218A1 (en) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc USEFUL HETEROCICLICAL COMPOUNDS AS PI3K INHIBITORS
JP2014525932A (en) 2011-08-15 2014-10-02 インターミューン， インコーポレイテッド Lysophosphatide acid receptor antagonist
MX2014002542A (en) 2011-08-29 2014-07-09 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof.
US9394283B2 (en) 2012-04-13 2016-07-19 Epizyme, Inc. Salt form of a human histone methyltransferase EZH2 inhibitor
PE20150887A1 (en) 2012-10-15 2015-06-04 Epizyme Inc SUBSTITUTE BENZENE COMPOUNDS
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
CA2894399A1 (en) 2012-12-06 2014-06-12 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
SG11201505283RA (en) * 2013-01-09 2015-08-28 Univ Michigan Mixed disulfide conjugates of thienopyridine compounds and uses thereof
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
KR102142177B1 (en) 2013-10-16 2020-08-07 에피자임, 인코포레이티드 Hydrochloride salt form for ezh2 inhibition
US20170217941A1 (en) * 2014-06-25 2017-08-03 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
WO2017007756A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc Hetero-halo inhibitors of histone deacetylase
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
HUE057849T2 (en) 2017-01-11 2022-06-28 Alkermes Inc Bicyclic inhibitors of histone deacetylase
LT3664802T (en) 2017-08-07 2022-06-27 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
EP3586847A1 (en) 2018-06-29 2020-01-01 Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca Compounds for use in preventing or treating cancer
EP3587416A1 (en) * 2018-06-29 2020-01-01 Institut Univ. de Ciència i Tecnologia, S.A. 2-oxopiperidin-3-yl derivatives and use thereof
CN109020874B (en) * 2018-09-04 2021-09-24 上海雅本化学有限公司 Apixaban intermediate and preparation method thereof
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US12378202B2 (en) * 2021-12-23 2025-08-05 Springworks Therapeutics, Inc. Tetrahydrobenzoazepinones and related analogs for inhibiting YAP/TAZ-TEAD
EP4356909A1 (en) 2022-10-17 2024-04-24 Selabtec Sciences, SLU 1-(sulfonyl)-n-phenylpyrrolidine-2-carboxamides derivatives and use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032602A (en) 1988-12-14 1991-07-16 Bayer Aktiengesellschaft Inhibiting HMG-CoA reductase with novel substituted 2-pyridones and pyrid-2-thiones
EP0454444A1 (en) 1990-04-24 1991-10-30 Nissan Chemical Industries Ltd. Glutarimide derivatives and herbicides
GB9026389D0 (en) 1990-12-05 1991-01-23 Merck Sharp & Dohme Therapeutic agents
US5246948A (en) 1991-05-10 1993-09-21 Takeda Chemical Industries, Ltd. Pyridine derivatives, their production and use
RU2140917C1 (en) 1993-11-19 1999-11-10 Парк, Дэвис энд Компани Derivatives of 5,6-dihydropyrone and pharmaceutical composition based on thereof
EP0923372A4 (en) 1996-02-22 2001-09-05 Merck & Co Inc PYRIDINONE THROMBINE INHIBITORS
CA2250353A1 (en) 1996-04-03 1997-10-09 Christopher J. Dinsmore Inhibitors of farnesyl-protein transferase
AU714985B2 (en) 1996-04-23 2000-01-13 Merck & Co., Inc. Pyrazinone thrombin inhibitors
AU4172397A (en) 1996-09-06 1998-03-26 Biochem Pharma Inc. Lactam inhibitors of thrombin
DE19647382A1 (en) 1996-11-15 1998-05-20 Hoechst Ag Heterocycles as inhibitors of leukocyte adhesion and VLA-4 antagonists
US6020357A (en) 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
EP0971891A4 (en) 1997-01-22 2000-04-19 Merck & Co Inc THROMBIN INHIBITORS
UA57081C2 (en) 1997-06-16 2003-06-16 Пфайзер Продактс Інк. FARNESYL TRANSFERASE INHIBITOR IN COMBINATION WITH HMG CoA REDUCTASE INHIBITORS USED FOR TREATING CANCER
EP0908764B1 (en) 1997-10-06 2002-03-27 Agfa-Gevaert Method of processing a black-and-white silver halide photographic material
AU1910299A (en) 1997-12-18 1999-07-05 Eli Lilly And Company Peptidomimetic template-based combinatorial libraries
WO1999031506A1 (en) 1997-12-18 1999-06-24 Eli Lilly And Company Parallel solution phase synthesis of lactams
ATE260103T1 (en) 1997-12-19 2004-03-15 Schering Ag ORTHO-ANTHRANILAMIDE DERIVATIVES AS ANTICOAGULANTS
WO1999042455A1 (en) 1998-02-19 1999-08-26 Tularik Inc. Antiviral agents
CA2360305A1 (en) 1999-02-09 2000-08-17 Bristol-Myers Squibb Company Lactam inhibitors of fxa and method
IL146244A0 (en) 1999-05-19 2002-07-25 Pharmacia Corp Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
NZ514877A (en) 1999-05-19 2004-10-29 Pharmacia Corp Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
BR0010758A (en) 1999-05-19 2003-06-10 Pharmacia Corp Substituted polycyclic aryl and heteroaryl pyrimidinones useful as anticoagulants
CZ20014115A3 (en) 1999-05-19 2002-05-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrazinones suitable for selective inhibition of coagulation cascade
DE19962924A1 (en) 1999-12-24 2001-07-05 Bayer Ag Substituted oxazolidinones and their use
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors

Also Published As

Publication number Publication date
JP2004536084A (en) 2004-12-02
EP1337251B1 (en) 2008-08-20
ES2310540T3 (en) 2009-01-16
US6951872B2 (en) 2005-10-04
US20020183324A1 (en) 2002-12-05
DE60135485D1 (en) 2008-10-02
CA2429113A1 (en) 2002-12-27
HUP0401832A2 (en) 2004-12-28
US20040132718A1 (en) 2004-07-08
EP1337251A1 (en) 2003-08-27
WO2002102380A1 (en) 2002-12-27
US6710058B2 (en) 2004-03-23

Similar Documents

Publication Publication Date Title
ATE405266T1 (en) MONOCYCLIC OR BIZYCLIC CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF FACTOR XA
ATE241621T1 (en) ARYLSULFONYLS AS FACTOR XA INHIBITORS
ATE371656T1 (en) HETEROARYL-PYRIMIDINE DERIVATIVES AS JAK INHIBITORS
NO20044995L (en) Heterocyclic compounds
ATE266636T1 (en) BENZIMIDAZOLINONE, BENZOXAZOLINONE, BENZOPIPERAZINONE, INDANONE AND THEIR DERIVATIVES AS FACTOR XA INHIBITORS
EA200400361A1 (en) DERIVATIVES OF ALKINARILNAFTHYRIDIN-4 (1H) -ONES AS A TYPE IV PHOSPHODYESTERASE INHIBITOR
ATE302775T1 (en) CARBOLINE DERIVATIVES
IL152916A0 (en) Heteroaryl-phenyl heterobicyclic factor xa inhibitors
EA200601686A1 (en) SUBSTITUTED DERIVATIVES OF MORPHOLINE AND THIOMORFOLINE
EA200300717A1 (en) Heterocyclylindazole and azazin-dazole compounds as 5-hydroxytriptamine-6-ligands
NO20060664L (en) N-substituted benzimidazolyl C-kit inhibitors
ATE408601T1 (en) FREDERICAMYCIN DERIVATIVES
DE69716925D1 (en) ISOXAZOLINE DERIVATIVES AND THEIR USE AS ANTIMICROBE
ATE477256T1 (en) THIENYL COMPOUNDS
DE60121461D1 (en) CONDENSED PYRIDOINDOL DERIVATIVES
DE60112306D1 (en) CONDENSED PYRAZINDION DERIVATIVES AS PDE5 INHIBITORS
ATE303384T1 (en) 1-BIARYL-1,8-NAPHTHYRIDINE-4-ONE AS PHOSPHODIESETERASE INHIBITORS
DE60321810D1 (en) NEW TRICYCL DERIVATIVES AS LTD4 ANTAGONISTS
EA200601176A1 (en) 3-CYANOHINOLINE DERIVATIVES WITH ANTIPROLIFERATIVE ACTIVITY
DE60112960D1 (en) CONDENSED PYRIDOINDOL DERIVATIVES
ATE391715T1 (en) HETEROCYCLIC MUTILINESTERS AND THEIR USE AS BACTERICIDES
SE9902267D0 (en) New compounds
DE60122559D1 (en) INDOLDERIVATE AS PDE5 INHIBITORS
EA200301101A1 (en) DERIVATIVES OF PIPERAZINE AND THEIR APPLICATION AS PDE4 INHIBITORS
NO20052994L (en) New phosphoramide derivatives.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties